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Background/aim: In the present study, the protective effect of erdosteine against cyclosporine-induced injury in rat liver was investigated
with histological and biochemical methods.
Materials and methods: Thirty-two Wistar albino male rats were randomly divided into 4 groups: control (n = 8), cyclosporine (n
= 8, 20 mg kg–1 day–1 i.p.), cyclosporine + erdosteine (n = 8, erdosteine 12 mg kg–1 day–1 orally), and erdosteine (n = 8). At the end
of day 12, liver tissues were removed for histological and biochemical analysis. After liver tissues were fixed in 10% buffered neutral
formalin, routine histological processes were applied and tissue sections were stained with hematoxylin and eosin, periodic acid–Schiff,
and elastic fiber stain methods. One hundred lobules of liver were examined for each group and evaluated statistically. The levels of
malondialdehyde and glutathione peroxidase, as well as the activities of superoxide dismutase, were determined.
Results: The cyclosporine group showed significant histopathological changes compared to the control. In the cyclosporine + erdosteine
group, histopathological changes of hepatic damage were markedly reduced. Histological findings were supported by biochemical results.
Conclusion: Erdosteine could attenuate cyclosporine-induced liver injury.
Key words: Cyclosporine, erdosteine, antioxidant system, hepatotoxicity

1. Introduction
Cyclosporine A (CsA), an immunosuppressive agent,
has been used in organ transplantation cases and the
treatment of autoimmune diseases for a long time (1,2).
It is a cyclic polypeptide with 11 amino acids, which is
produced by fermentation of Trichoderma polysporum
and Cylindrocarpon (3). Cyclosporine G, formed by
replacement of alpha-aminobutyric acid by norvaline, has
an identical effect to that observed with CsA (4,5).
From the 1980s onwards, side effects began to
occur with the wide prescription of CsA. These include
nephrotoxicity, cardiotoxicity, hypertension, infections,
and hepatotoxicity (6–8).
The mechanism of tissue damage caused by CsA has
not been fully understood. Several authors have suggested
* Correspondence: drnacar@gmail.com
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that reactive oxygen species production, oxidative stress,
and depletion of the hepatic antioxidant system are
possible mechanisms of CsA hepatotoxicity (9,10).
Although the mechanism of CsA side effects is not
fully understood, several studies showed that the use of
antioxidant agents can reduce the toxicity (10,11).
Erdosteine [N-(carboxymethylthioacetyl)-homocysteine thiolactone] is a mucolytic agent that was developed
for the treatment of chronic pulmonary disease. Erdosteine
includes two blocked sulfhydryl groups that are unlocked
with hepatic metabolization. The reducing potential of
these sulfhydryl groups provides antioxidant activity and
free radical scavenging of erdosteine (12,13).
Erdosteine is known to have antioxidant properties
and has been used in many studies on account of its
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scavenging activity. Those studies demonstrated the free
radical scavenging abilities of erdosteine with biochemical
and histological methods (14,15).
Organ transplants are vital for many patients, and
the number of patients undergoing organ transplants
is increasing. CsA is the most effective drug used in the
treatment of organ transplant rejections and autoimmune
disease. However, its administration is limited because of
its serious side effects. Therefore, it was aimed to investigate
the protective effect of erdosteine against CsA-induced
hepatotoxicity in rats with histological and biochemical
methods in the present study.
2. Materials and methods
Our study was approved by the animal ethics committee
of Mustafa Kemal University, and experiments were
performed in accordance with the principles of the
Animal Welfare Act and the Guide for the Care and Use
of Laboratories. Thirty-two male Wistar albino rats (aged
8–12 weeks) weighing 250 ± 20 g (mean ± standard
deviation) were obtained for this study from the Laboratory
Animal Production Unit of Çukurova University. The rats
were kept in a room under controlled temperature (20 ± 2
°C) and humidity (50 ± 5%) with a 12-h light/dark cycle
for 1 week before the onset of the experiment. Standard
diet and tap water were provided ad libitum.
Rats were randomly divided into 4 equal experimental
groups as follows. In the control group, group 1 (n = 8), 1
mL of 0.9% NaCl was injected intraperitoneally into the
animals. In the CsA group, group 2 (n = 8), 20 mg kg–1
day–1 of CsA (Sandimmune 50 mg/mL vial, Novartis)
was diluted in physiological saline and 2 mL of this
solution was administered intraperitoneally. In the CsA +
erdosteine group, group 3 (n = 8), 20 mg kg–1 day–1 of CsA +
erdosteine (Sandoz, Erdostin 300 mg/capsule), erdosteine
was administered by oral gavage in 10 mg/kg doses for
12 days. Erdosteine was dissolved in distilled water with
NaHCO3 and was given orally once a day. In the erdosteine
group, group 4 (n = 8), only erdosteine was administered
in doses of 10 mg/kg for 12 days by oral gavage.
At the end of day 12, the rats were anesthetized with
ketamine hydrochloride (50 mg/kg i.m., Ketalar, Turkey)
and sacrificed. The left lobe of the liver was dissected and
stored at –70 °C until biochemical analysis. The right lobe
of the liver was used for histopathological analysis.
For light microscopic evaluation, liver tissue samples
were fixed in 10% neutral buffered formalin. After
fixation and routine histological procedure, samples
were embedded in paraffin and sectioned at 5 µm with
a microtome. Afterward, the sections were stained with
hematoxylin and eosin (H&E, Sigma-Aldrich MHS 128HT110180, USA), periodic acid–Schiff (PAS, SigmaAldrich 395B, USA), and elastic fiber stain (Sigma-

Aldrich 395B, USA) and were then examined with a BX51
microscope (Olympus, Japan) and photographed.
In total, 100 lobules of liver for each group were
examined by two blinded histologists using H&E-stained
sections. Histopathological findings such as sinusoidal
dilatation, inflammatory cell infiltration, hepatocellular
vacuolization, and hemorrhage were identified in 100
lobules of each group and then scored. The histological
changes were graded as follows: normal = 0, mild = 1,
moderate = 2, severe = 3 (16).
Liver tissues were homogenized for 2 min at 5000
rpm in 4 volumes of ice-cold Tris-HCl buffer (50 mM,
pH 7.4) with a homogenizer to measure malondialdehyde
(MDA) and protein levels. To obtain the supernatant,
the homogenates were centrifuged at 5000 × g for 60
min. Supernatant fluids were then collected and kept
at –40 °C for glutathione peroxidase (GSH-Px) activity
determination. The supernatant solutions were treated
with an equal volume of a mixture including ethanol and
chloroform (5:3 volumes per volume [5⁄3]). The mixture
was then centrifuged at 5000 × g for 30 min. The clear
upper layer (the ethanol phase) was collected for the
measurement of superoxide dismutase (SOD) activity and
protein assays.
SOD activity was measured based on a method
adapted from Sun et al. (17). With this method, nitroblue
tetrazolium reduction is inhibited by the xanthinexanthine oxidase system. The MDA level was assessed
by a method in which MDA reacts with thiobarbituric
acid at 90–100 °C (18). GSH-Px (EC 1.6.4.2) activity
was determined using a method described by Paglia and
Valentine (19). The method of Lowry et al. was utilized for
protein assays (20).
In addition to histological methods, hepatic injury
was evaluated biochemically using serum aspartate
transaminase (AST) and alanine transaminase (ALT)
levels. Serum levels of AST and ALT were determined
with commercial Beckman Coulter diagnostic kits and
automated enzyme analyzers (Syncron LX 20, Ireland).
SPSS 11.5 for Windows was used for the statistical
assessment of the obtained data. Results are presented as
means ± standard error of the mean (SEM); P < 0.05 was
regarded as statistically significant.
3. Results
MDA levels were significantly higher in the CsA group
in comparison to the control (P < 0.05). MDA was
significantly lower in the CsA + erdosteine group than in
the CsA group (P < 0.05). SOD and GSH-Px activities were
significantly decreased in the CsA group compared to the
control group (P < 0.001). Additionally, SOD and GPx
activities were significantly higher in the CsA + erdosteine
group compared to the CsA group (P < 0.05). There was a
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statistically significant increase in AST and ALT levels in
the CsA group when compared to the control group (P <
0.05). AST and ALT levels decreased significantly in the
CsA + erdosteine group compared to the CsA group (P <
0.05) (Figures 1A–1E).
Light microscopic evaluation of the control group
revealed a regular morphology of liver parenchyma with
intact hepatocytes and sinusoids. In the CsA group,
major histopathological changes were the dilatation of
the sinusoids, vacuolization of hepatocytes, hemorrhage,
and inflammatory cell infiltration of the parenchyma.
These histopathological changes were confirmed by PAS
and elastic fiber stains. In the CsA + erdosteine group,
minimal inflammatory cell invasion and congestion was
seen. In the erdosteine group, no pathological changes in
liver histology were observed (Figures 2A–2D).

In the CsA group, histopathological scores were
significantly higher compared to the control. In the CsA +
erdosteine group, a significantly decreased morphological
score was obtained compared to the CsA group. All scores
are given in the Table.
4. Discussion
Since the 1980s, CsA has been used widely in many
immunological diseases and in the prevention of rejection
reactions in organ transplantation (8). This agent is a
fungal cyclic peptide and a strong immunosuppressive
(21).
The use of CsA has increased the quality and
duration of life in transplantation patients. Its use is
limited by significant side effects such as nephrotoxicity,
hepatotoxicity, cardiotoxicity, and hypertension (22–25).

Figure 1. A–B: SOD and GSH-Px activities were significantly decreased in group 2 compared to the control group (P < 0.001).
Additionally, SOD and GPx activities were significantly higher in group 3 than in group 2 (P < 0.05). C: MDA levels were significantly
higher in group 2 in comparison to the control group (P < 0.05). MDA was significantly lower in group 3 than in group 2 (P < 0.05).
D–E: ALT and AST levels were significantly increased in group 2 as compared to the control group (P < 0.05), whereas ALT and AST
levels were significantly lower in group 3 than in group 2 (P < 0.05). Group 1: Control, 2: cyclosporine, 3: cyclosporine + erdosteine,
4: erdosteine.
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Figure 2. A: Control group showed normal hepatic lobule structure; B: erdosteine group showed normal hepatic lobule structure;
C: congestion (arrow head), sinusoidal dilatation (*), and inflammatory cell infiltration (arrow) in CsA group; D: improved lobule
histology in CsA + erdosteine group.
Table. Scores of histological changes in all groups.
Groups

Sinusoidal
dilatation

Vacuolization of
hepatocytes

Hemorrhage

Inflammatory cell
infiltration

Control

0

0

0

0

CsA

2.79 ± 0.43

1.24 ± 0.66

2.58 ± 0.47

2.41 ± 0.53

CsA + erdosteine

1.40 ± 0.68

0.88 ± 0.52

1.33 ± 0.62

1.23 ± 0.55

Erdosteine

0

0

0

0

Compared groups

P-values

Group 1–Group 2

0.000*

0.000*

0.000*

0.000*

Group 1–Group 3

0.000*

0.000*

0.000*

0.000*

Group 1–Group 4

1.000

1.000

1.000

1.000

Group 2–Group 3

0.000*

0.000*

0.000*

0.000*

Group 2–Group 4

0.000*

0.000*

0.000*

0.000*

Group 3–Group 4

0.000*

0.000*

0.000*

0.000*

Results are expressed as the mean ± standard error of the mean (SEM); *: Statistically significant.
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Hepatotoxicity is one of its most dangerous side effects
(26).
The mechanism underlying hepatic side effects of the
drug has not been fully understood yet despite extensive
investigations. Findings indicate that reactive oxygen
species (ROS) increase the oxidative damage (21).
In vivo and in vitro studies have shown that CsA, having
a lipophilic structure, easily attaches to cell membranes by
inducing lipid peroxidation in the membrane to cause free
radical formation (27,28).
Free radicals increase lipid peroxidation by reacting
with intracellular molecules such as phospholipid,
glycolipid, and glycerides. Thus, the cell ion gradient and
permeability are disrupted. This results in an increase in
ROS synthesis, which can cause irreversible cell damage
unless prevented by antioxidant mechanisms (29,30).
A study by Hagar et al. showed that hyperbilirubinemia,
cholestasis, increased ALP and transaminases, and
inhibition of protein synthesis are the key findings of CsA
hepatotoxicity in both laboratory animals and humans
(31). We also found increased AST and ALT levels in the
CsA group.
MDA is an important end product of lipid peroxidation
and is also an indicator of free radical-induced tissue
damage. Several studies showed that CsA causes an
increase in the liver tissue MDA level (14,32). In our study,
there was a statistically significant increase in liver MDA
levels of the CsA group compared to the control and the
CsA + erdosteine groups.
Antioxidant enzymes, such as SOD and GSH-Px, are
protective against free radicals. SOD catalyzes dismutation
of the superoxide anion (O2-) into hydrogen peroxide
(H2O2), which is then detoxified to H2O by catalase. GSH
and GSH-Px convert H2O2 and lipid peroxides to nontoxic
products when entering the glutathione redox cycle. CsA
decreases the activity of one or more antioxidant systems

with a direct toxic effect, leading to increased oxidative
stress and lipid peroxidation (27). In our study, liver SOD
and GSH-Px levels decreased significantly in the CsA
group compared to the control and CsA + erdosteine
group. Similarly, Kaya et al. reported decreased SOD and
GSH-Px levels in CsA-treated rats (33).
CsA hepatotoxicity has been shown histologically
in many experimental studies. CsA treatment causes
disorganization of hepatocyte cords, vacuolization,
and dilatation in liver parenchyma (16,34,35). Our
histopathological findings are in line with previous studies.
Additionally, we performed two more stains to detect
histological changes, which supported the H&E findings.
Many experimental studies have used erdosteine against
hepatotoxic damage and the protective effect of erdosteine
was shown by histological and biochemical methods (36).
Sahin et al. demonstrated that oral erdosteine treatment
had strong antioxidant activity against vancomycininduced liver hepatotoxicity in rats (35).
Eraslan et al. demonstrated the protective effect of
erdosteine against CsA-induced hepatotoxicity in rats (37).
They reported decreased MDA, AST, and ALT levels and
improved morphology in the erdosteine-administrated
group compared to the CsA group; however, no significant
changes in GSH-Px and SOD levels were observed. They
supported the antioxidant activity of erdosteine with
decreased nitric oxide and increased catalase activities. On
the other hand, Andrés et al. and Durak et al. reported that
CsA administration significantly reduced the antioxidant
capacity in the hepatic tissues of the animals (38,39).
These histological and biochemical findings suggest
that the damage caused by CsA is preventable and could be
reduced by erdosteine treatment through its antioxidant
and radical scavenging effects. Further studies should be
carried out in order to document the effects of erdosteine
during long-term use of CsA.
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